Nemucore Medical Innovations Wins Phase I U43 Small Business Innovation Research Grant

WORCESTER, Mass. - May 8, 2013 - PRLog -- Nemucore Medical Innovations, Inc. (NMI), announces that it has received a Phase I U43 Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to develop a targeted nanomedicine for the treatment of multidrug resistant ovarian cancer, designated NMI-700. NMI-700 is designed to accumulate high doses of chemotherapy in ovarian tumors and release it in a controlled manner.

During treatment recurrent cancers build up multidrug resistance to conventional and novel chemotherapeutic agents, representing a formidable challenge in clinical cancer therapy, especially for the effective treatment of gynecological malignancies.  Our overarching strategy addresses the major failures of the first line therapy by using multifunctional nanomedicines to target and eradicate chemosensitive and chemoresistant tumor cells.

This year long U43 program will assess the ability of NMI-700 to enhance the pharmacokinetics and pharmacodynamics of a clinically relevant chemotherapeutic and move the NMI-program one step closer to the clinic.

NMI President and CEO Dr. Tim Coleman states that this work will make an impact on patient care, "Nanomedicine development is complex and at a very nascent stage of commercialization. NMI focuses on developing novel concepts by engineering sophisticated molecular entities with desirable clinical characteristics to develop life saving products for ovarian cancer patients.”

The nanomedicine technology is the result of a collaboration between Drs. Valdimir Torchilin, who runs Northeastern University’s U54 funded Center for Cancer Nanotechnology Excellence, and Yuri Lvov, Professor at Lousiana Tech University’s Institute for Micromanufacturing. Both Drs. Torchilin and Lvov are founders of NMI.

About Nemucore Medical Innovations:
Nemucore Medical Innovations, Inc. is dedicated to designing, investigating, developing, and commercializing life-saving nanomedicines for the treatment of ovarian cancer. Ultimately, we believe our products will be part of the personalized medicine revolution occurring in cancer therapies. Our unique focus on reducing the complex nature of nanomedicine manufacturing is expected to enhance the speed by which we translate novel therapeutics to the clinic. As a participant in the National Cancer Institute's Centers for Cancer Nanotechnology Excellence, we are building a state of the art biomanufacturing facility as a national resource for nanomedicine and emerging biopharmaceutical community. NMI was founded in 2008 and is based in Worcester and Wellesley, Massachusetts. For more information, please visit http://www.nemucore.com.